Management of anthrax

Clinical Infectious Diseases

Volumn 35, Issue 7, 2002, Pages 851-858

  Bartlett, John G ^a   Inglesby, Thomas V ^a   Borio, Luciana ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CALCIUM CHANNEL BLOCKING AGENT; CEFTRIAXONE; CIPROFLOXACIN; CLARITHROMYCIN; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXYCYCLINE; ERYTHROMYCIN; IMMUNOGLOBULIN; PENICILLIN DERIVATIVE; RIFAMPICIN; TETRACYCLINE; VANCOMYCIN;

ANTHRAX; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL SPORE; BIOLOGICAL WARFARE; CLINICAL FEATURE; FINANCIAL MANAGEMENT; HEALTH CARE SYSTEM; INCUBATION TIME; MEDICAL RESEARCH; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH; THORAX RADIOGRAPHY;

ANTHRAX; ANTIBIOTIC PROPHYLAXIS; BIOLOGICAL WARFARE; BIOTERRORISM; DISEASE MANAGEMENT; DISEASE OUTBREAKS; HUMANS; SKIN DISEASES, BACTERIAL; UNITED STATES;

EID: 0036788371     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/341902     Document Type: Article

References (28)

1. Bush LM, Abrams BH, Beall A, Johnson CC. Index case of fatal inhalation anthrax due to bioterrorism in the United States. N Engl J Med 2001; 345:1607-10.
2. Centers for Disease Control and Prevention. Update: investigation of anthrax associated with intentional exposure and interim public health guidelines, October 2001. MMWR Morb Mortal Wkly Rep 2001; 50:889-91.
3. Kennedy H. Daschle letter bombshell - billions of anthrax spores. New York Daily News, 31 October 2001:5.
4. Friedlander AM, Welkos SL, Pitt MLM, et al. Postexposure prophylaxis against inhalation anthrax. J Infect Dis 1993; 167:1239-42.
5. Inglesby TV, Henderson DA, Bartlett JG, et al. Anthrax as a biological weapon: updated recommendations for management. JAMA 2002; 287:2236-52.
6. Broad W. A nation challenged: the disease - geographic gaffe misguides anthrax inquiry. New York Times, 30 January 2002:A11.
7. Centers for Disease Control and Prevention. Update: investigation of bioterrorism-related anthrax and interim guidelines for clinical evaluation of persons with possible anthrax. MMWR Morb Mortal Wkly Rep 2001; 50:941-8.
8. Centers for Disease Control and Prevention. Update: investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy. MMWR Morb Mortal Wkly Rep 2001; 50:909-19.
9. Centers for Disease Control and Prevention. Interim guidelines for investigation of and response to Bacillus anthracis exposures. MMWR Morb Mortal Wkly Rep 2001; 50:987-90.
10. Centers for Disease Control and Prevention. Additional options for preventive treatment for persons exposed to inhalational anthrax. MMWR Morb Mortal Wkly Rep 2001; 50:1142-51.
11. Centers for Disease Control and Prevention. Update: interim recommendations for antimicrobial prophylaxis for children and breastfeeding mothers and treatment of children with anthrax. MMWR Morb Mortal Wkly Rep 2001; 50:1014-6.
12. Inglesby TV, Henderson, DA, Bartlett JG. Anthrax as a biological weapon: medical and public health management. JAMA 1999; 281:1735-45.
13. Bell DM, Kozarsky PE, Stephens DS. Clinical issues in the prophylaxis, diagnosis and treatment of anthrax. Emerg Infect Dis 2002; 8:222-5.
14. Jernigan JA, Stephens DS, Ashford DA, et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 2001; 7:933-44.
15. CDC update: investigation of bioterrorism-related inhalation anthrax - Connecticut 2001. MMWR Morb Mortal Wkly Rep 2001; 50:1049-51.
16. Grinberg LM, Abramova FA, Yampolskaya OV, et al. Quantitative pathology of inhalational anthrax I: quantitative microscopic findings. Mod Pathol 2001; 14:482-95.
17. Borio L, Frank D, Mani V, et al. Death due to bioterrorism-related inhalational anthrax: report of two patients. JAMA 2001; 286:2554-9.
18. Brachman PS. Inhalation anthrax. Ann N Y Acad Sci 1980; 353:83-93.
19. Henderson DW, Peacock S, Belton FC. Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J Hyg 1956; 54:28-36.
20. National Institutes of Health, Office of Public Health Preparedness, Centers for Disease Control and Prevention. Optimizing post-exposure prevention of inhalation anthrax: issues and options. Washington, DC: National Academy of Sciences, 2001.
21. Kournikakis B, Armour SJ, Boulet CA, et al. Risk assessment of anthrax threat letters. TR-2001-048. Suffield: Defense Research Establishment.
22. Abramova FA, Grinberg LM, Yampolskaya OV, Walker DH. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak in 1979. Proc Natl Acad Sci USA 1993; 90:2291-4.
23. Stepanov AV, Mariniu LI, Pomeratsev AP, et al. Development of novel vaccines against anthrax in man. J Biotechnol 1996; 44:155-60.
24. Centers for Disease Control and Prevention. Additional options for preventive treatment for exposed persons to inhalation anthrax. JAMA 2002; 287:579.
25. Centers for Disease Control and Prevention. Human anthrax associated with an epizootic among livestock - North Dakota, 2000. MMWR Morb Mortal Wkly Rep 2001; 50:677-80.
26. Freedman A, Afonja O, Chang MW, et al. Cutaneous anthrax associated with microangiopathic hemolytic anemia and coagulopathy in a 7-month-old infant. JAMA 2002; 287:869-74.
27. Hail AS, Rossi CA, Ludwig GW, et al. Comparison of noninvasive sampling sites for early detection of Bacillus anthracis spores from rhesus monkeys after aerosol challenge. Mil Med 1999; 164:833-7.
28. Friedlander AM, Pittman PR, Parker GW. Anthrax vaccine: evidence for safety and efficacy against inhalational anthrax. JAMA 1999; 282:2104-6.